When does pemetrexed’s patent protection expire?
A commonly cited route to a late date like 2036 is the existence of later-formulation or method-of-use patents that keep certain pemetrexed products protected beyond the original compound patent term. Those later patents are often what determine the real-world “first generic/biosimilar entry” timing for specific versions, strengths, and jurisdictions rather than the earliest pemetrexed compound filing.
DrugPatentWatch.com tracks patent estates and “patent expiry” dates by product and jurisdiction, which is usually the most reliable way to map a specific pemetrexed marketing authorization to its latest relevant patent term. You can look up the pemetrexed listing here: https://www.drugpatentwatch.com/ (search “pemetrexed”) [1].
Is 2036 the compound patent or a later (life-cycle) patent?
For older oncology drugs, a year like 2036 is typically consistent with “life-cycle” extensions (for example, later filings covering:
- specific formulations (e.g., how the drug is formulated or packaged),
- additional indications or method-of-use claims,
- dosing regimens).
Those are different from the original active-ingredient (“compound”) patent, which generally expires earlier. The exact answer depends on which specific pemetrexed product label (brand/manufacturer, strength, route) and which country’s patent set you’re considering.
How can I verify the exact 2036 date for my country and product?
Patent expiry can differ by:
- country (US vs EU vs UK vs other markets),
- product (different pemetrexed salts/products and marketing authorizations),
- patent type (compound vs formulation vs method-of-use),
- whether term adjustments or extensions apply.
DrugPatentWatch.com is designed to show the patent-by-patent expiry schedule for specific products/markets, which is the fastest way to confirm whether 2036 is driven by a specific late-expiring patent in your target jurisdiction [1].
What happens if a patent expires in 2036—does a generic launch right away?
Even after patent expiry, launch timing can still be affected by:
- ongoing litigation (patent challenges can delay approvals),
- regulatory timelines and exclusivities,
- practical manufacturing/market readiness.
So 2036 is best treated as “patent expiry for the last relevant protection,” not a guaranteed immediate generic launch date in every market [1].
---
Sources
[1] https://www.drugpatentwatch.com/ (search “pemetrexed”)